Overcoming therapy resistance in EGFR-mutant lung cancer
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
J Wang, B Wang, H Chu, Y Yao - OncoTargets and therapy, 2016 - Taylor & Francis
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …
[HTML][HTML] Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Lung cancer is the leading cause of cancer related deaths in Canada with non-small cell
lung cancer (NSCLC) being the predominant form of the disease. Tumor characterization …
lung cancer (NSCLC) being the predominant form of the disease. Tumor characterization …
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib
Y Xu, H Liu, J Chen, Q Zhou - Cancer biology & therapy, 2010 - Taylor & Francis
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …
EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
RF Dong, ML Zhu, MM Liu, YT Xu, LL Yuan… - Pharmacological …, 2021 - Elsevier
With the development of precision medicine, molecular targeted therapy has been widely
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …
Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients
L Lin, TG Bivona - Chemotherapy research and practice, 2012 - Wiley Online Library
The epidermal growth factor receptor (EGFR) is a well‐characterized oncogene that is
frequently activated by somatic kinase domain mutations in non‐small cell lung cancer …
frequently activated by somatic kinase domain mutations in non‐small cell lung cancer …
[HTML][HTML] Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel …
M Johnson, MC Garassino, T Mok, T Mitsudomi - Lung Cancer, 2022 - Elsevier
Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
[HTML][HTML] Strategies to improve outcomes of patients with EGFR-mutant non–small cell lung cancer: review of the literature
C Zhou, L Di Yao - Journal of Thoracic Oncology, 2016 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny
K Suda, H Mizuuchi, Y Maehara… - Cancer and Metastasis …, 2012 - Springer
Lung cancers that harbor somatic activating mutations in the gene for the epidermal growth
factor receptor (EGFR) depend on mutant EGFR for their proliferation and survival; therefore …
factor receptor (EGFR) depend on mutant EGFR for their proliferation and survival; therefore …
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non‐small‐cell lung cancer
T Kosaka, E Yamaki, A Mogi… - BioMed Research …, 2011 - Wiley Online Library
Gefitinib and erlotinib, which are epidermal growth factor receptor‐(EGFR‐) specific tyrosine
kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non‐small‐cell …
kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non‐small‐cell …